Quadrivalent Influenza Virus Split Vaccine — Competitive Intelligence Brief

Quadrivalent Influenza Virus Split Vaccine (Quadrivalent Influenza Virus Split Vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated split influenza vaccine. Area: Immunology.

marketed Inactivated split influenza vaccine Immunology Biologic

Target snapshot

Quadrivalent Influenza Virus Split Vaccine (Quadrivalent Influenza Virus Split Vaccine) — Shanghai Institute Of Biological Products. This vaccine stimulates the immune system to produce antibodies and cellular immunity against four strains of influenza virus.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Quadrivalent Influenza Virus Split Vaccine TARGET	Quadrivalent Influenza Virus Split Vaccine	Shanghai Institute Of Biological Products	marketed	Inactivated split influenza vaccine
Inactivated Split Influenza Vaccine	Inactivated Split Influenza Vaccine	St. Petersburg Research Institute of Vaccines and Sera	phase 3	Inactivated split influenza vaccine
Influenza split vaccine	Influenza split vaccine	Hualan Biological Engineering, Inc.	phase 3	Inactivated split influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated split influenza vaccine class)

1. Hualan Biological Engineering, Inc. · 1 drug in this class
2. Shanghai Institute Of Biological Products · 1 drug in this class
3. St. Petersburg Research Institute of Vaccines and Sera · 1 drug in this class